Target Blood Pressure in Patients with Diabetes: Asian Perspective.
10.3349/ymj.2016.57.6.1307
- Author:
Sungha PARK
1
;
Kazuomi KARIO
;
Chang Gyu PARK
;
Qi Fang HUANG
;
Hao Min CHENG
;
Satoshi HOSHIDE
;
Ji Guang WANG
;
Chen Huan CHEN
Author Information
1. Division of Cardiology, Cardiovascular Hospital, Yonsei Health System, Seoul, Korea.
- Publication Type:Review
- Keywords:
Diabetes;
hypertension;
blood pressure;
stroke J-curve;
coronary artery disease
- MeSH:
Asian Continental Ancestry Group*;
Blood Pressure*;
Coronary Artery Disease;
Humans;
Hypertension;
Incidence;
Mortality;
Ramipril;
Stroke;
Verapamil
- From:Yonsei Medical Journal
2016;57(6):1307-1311
- CountryRepublic of Korea
- Language:English
-
Abstract:
Recently, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) blood pressure (BP) trial enrolled 4733 participants with type 2 diabetes and randomized them to a target systolic blood pressure (SBP) of less than 120 mm Hg or 140 mm Hg. Despite the significant difference in the achieved SBP, there was no significant difference in the incidence of primary outcomes. Based on this evidence, the target SBP for diabetics has been revised in the majority of major guidelines. However, there is a steeper association between SBP and stroke in Asians than other ethnicities, with stroke being the leading cause of cardiovascular mortality. This suggests that target BP in the Asian region should be tailored towards prevention of stroke. In the ACCORD study, the intensive BP treatment was associated with significant reductions in both total stroke and non-fatal stroke. The results from the ACCORD study are supported by a subgroup analysis from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study, which showed that, in diabetic patients, the risk of stroke continues to decrease to a SBP value of 115 mm Hg with no evidence of J curve. As diabetes is highly associated with underlying coronary artery disease, there is a justified concern for adverse effects resulting from too much lowering of BP. In a post hoc analysis of 6400 diabetic subjects enrolled in the International Verapamil SR-Trandolapril (INVEST) study, subjects with SBP of less than 110 mm Hg were associated with a significant increase in all-cause mortality. In the ONTARGET study, at any levels of achieved SBP, diastolic blood pressure (DBP) below 67 mm Hg was associated with increased risk for cardiovascular outcomes. As such, a prudent approach would be to target a SBP of 130–140 mm Hg and DBP of above 60 mm Hg in diabetics with coronary artery disease. In conclusion, hypertension, in association with diabetes, has been found to be significantly correlated with an elevated risk for cardiovascular events. As the association between stroke and BP is stronger in Asians, compared to other ethnicities, consideration should be given for a target BP of 130/80 mm Hg in Asians.
